Table 2 NcRNA-based anti-angiogenesis therapies in lung cancer
From: Non-coding RNAs in lung cancer: emerging regulators of angiogenesis
Therapeutic tools | Type | Targets | Functions | References |
|---|---|---|---|---|
Nucleolin aptamer-siRNA chimaeras | siRNA | SLUG and NRP1 | Suppress lung cancer cell invasion, tumor growth and angiogenesis | [96] |
Bivalent cyclic RGD-siRNA conjugate | siRNA | VEGFR2 | Inhibiting neovascularization and proliferation on NSCLC xenografts | [97] |
siRNA nanoemulsions | siRNA | CXCR4 and STAT3 | Inhibit tumor proliferation and neovascularization in lung metastases | [99] |
Global miRNA depletion | Endoribonuclease | FIH1/HIF pathway | Suppress angiogenesis in NSCLC cell line and xenografts | [101] |
miR-16/322/497/17 | miRNA | VEGFR2 | Inhibit tumor angiogenesis in a murine Lewis lung cancer model | [103] |
miR-125b | miRNA | VE-cadherin | Inducing nonfunctional blood vessel formation to inhibit tumor growth | [104] |
Multi-functional NPs | siRNA | VEGF | Inhibits tumor proliferation and angiogenesis in orthotopic NSCLC | [105] |